An interventional study of Astaxanthin Oral Capsule and Matched Placebo (Capsules) in Asthma (Diagnosis), Airway Inflammation and Airway Hyperresponsiveness, sponsored by Middlesex University. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-02.
Sponsored by Middlesex University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 558 studies in Asthma with a site in United Kingdom — 52 open to participants now, 71 under way, 11 of them phase 3. Asthma · United Kingdom.
Among the 558 studies in Asthma with a site in United Kingdom, this one is the 341st largest by planned enrollment of the 427 interventional ones that give a count, is one of 17 that started in 2026, is one of 87 with no phase, reaches primary completion later than 19 of the 70 other live ones, and was the 551st registered.
4,846 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →52 of the 558 studies in Asthma with a site in United Kingdom are open now. Recruiting first, the newest first:
Richmond Research Institute · Sites in United Kingdom
Ages 18+
Chiesi Farmaceutici S.p.A. · Sites in United Kingdom
Ages 18–65 · Healthy volunteers
Liverpool Heart and Chest Hospital NHS Foundation Trust · Sites in United Kingdom
Ages 18–110
GlaxoSmithKline · Sites in United Kingdom, United States, Argentina and 1 more country
Ages 18+
University of Leeds · Sites in United Kingdom
Ages 18–70
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
558 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 87 · Phase 2 132 · Phase 3 83 · Phase 4 50
First in 1991; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 69 across the 427 interventional studies, 149 across the 131 observational. Of the 445 that completed or were terminated, 155 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
320 of 558 have an industry lead sponsor. The 10 most frequent:
Middlesex University is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Middlesex University has 1 study filed under Asthma — fewer than ten, so there is no comparison to draw.
23 of the studies in Asthma with a site in United Kingdom that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT07645248Phase 3GlaxoSmithKlineA Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) | 2026-12-28 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT07833826University of NottinghamN-WATCH: Nottingham Wheeze Assessment in Tidal Children | 2026-12-31 |
| NCT07488897RIGImmune Inc.RIG 101 Trial in Healthy Adults and Adults With Asthma | 2027-02 |
Add all 23 to your calendar (.ics) → With an account.
Among the 558 studies in Asthma with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will test whether astaxanthin, a naturally occurring antioxidant supplement, can improve lung function, reduce airway inflammation, and improve asthma control in adults with mild-to-moderate asthma. Participants will receive astaxanthin and placebo in random order in a double-blind crossover design. Each treatment period lasts 4 weeks and is separated by a 3-week washout period. The study also measures indoor and personal air pollution exposure to examine whether pollution influences asthma symptoms, airway responsiveness, and response to treatment. Exploratory thoracic bioelectrical impedance spectroscopy will be assessed alongside standard respiratory tests.
This is a randomized, double-blind, placebo-controlled, 2-sequence, 2-period crossover trial in 25 non-smoking, non-vaping adults aged 18 to 59 years with mild-to-moderate asthma or asthma-like symptoms confirmed at screening. Participants will be allocated 1:1 to one of two treatment sequences: astaxanthin followed by placebo, or placebo followed by astaxanthin. Each intervention period lasts 4 weeks and is separated by a 3-week washout. Astaxanthin will be given orally at a total dose of 12 mg/day as three 4 mg capsules taken with the participant's largest meal; placebo capsules will be matched. Outcome assessments include FeNO, spirometry, impulse oscillometry, body plethysmography, hypertonic saline challenge with induced sputum collection, home peak expiratory flow monitoring, questionnaires, and exploratory thoracic bioelectrical impedance spectroscopy. Indoor and personal air pollution exposures will be measured throughout the study to evaluate whether pollution modifies respiratory outcomes and treatment response.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Confirmed clinical diagnosis of mild-to-moderate asthma, defined as:
(those with suspected Asthma will be invited to a familiarisation and eligibility session where they will have clinical investigations to assess for asthma and thus be included or excluded)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive astaxanthin 12 mg/day orally for 4 weeks, followed by a 3-week washout, then matched placebo orally for 4 weeks.
Dietary Supplement: Astaxanthin Oral Capsule · Dietary Supplement: Matched Placebo (Capsules)
Participants receive matched placebo orally for 4 weeks, followed by a 3-week washout, then astaxanthin 12 mg/day orally for 4 weeks.
Dietary Supplement: Astaxanthin Oral Capsule · Dietary Supplement: Matched Placebo (Capsules)
Natural astaxanthin derived primarily from Haematococcus pluvialis, administered orally as three 4 mg capsules daily (total 12 mg/day) with the participant's largest meal for 4
Matched placebo capsules administered orally once daily as three capsules with the participant's largest meal for 4 weeks.
Change in Forced Expiratory Volume in 1 Second (FEV1)
FEV1 measured by spirometry using a calibrated Medisoft BodyBox system. Comparison is within-participant change after astaxanthin versus placebo.
Time frame: Measured at period-specific baseline and restablishment of baseline after washout period and end of each 4-week treatment period
Change in Fractional Exhaled Nitric Oxide (FeNO)
FeNO measured in parts per billion using the NIOX VERO analyser. Comparison is within-participant change after astaxanthin versus placebo.
Time frame: Measured at period-specific baseline and restablishment of baseline after washout period and end of each 4-week treatment period
Change in Airway Hyperresponsiveness During Hypertonic Saline Challenge
Hypertonic saline challenge response quantified using the dose response slope
Time frame: Measured at period-specific baseline and end of each 4-week treatment period
Change in Impulse Oscillometry Resistance at 5 Hz (R5)
R5 measured during tidal breathing using the PulmoScan system
Time frame: Baseline, end of phase 1, post washout and end of phase 2
Change in Impulse Oscillometry Area of Reactance (AX)
AX measured using the PulmoScan system as an index of peripheral airway involvement.
Time frame: Baseline, end of phase 1, post washout and end of phase 2
Change in Asthma Control Questionnaire-6 (ACQ-6) Total Score
Participant-reported asthma control measured using the ACQ-6.
Time frame: Weekly during the 11- to 12-week study period
Change in Asthma Quality of Life Questionnaire (AQLQ) Total Score
Every 2 weeks during the 11- to 12-week study period
Time frame: Participant-reported asthma-related quality of life measured using the AQLQ.
Change in Peak Expiratory Flow Amplitude Percent Mean (PEF APM)
Diurnal variability in peak expiratory flow derived from home morning and evening PEF
Time frame: Twice daily during each treatment period and washout, up to 11 to 12 weeks
Change in Sputum Eosinophil Percentage
Baseline, end of phase 1, post washout period and end of phase 2
Time frame: Induced sputum cellular differential measured after hypertonic saline challenge.
Change in Sputum Interleukin-8 (IL-8) Concentration
Baseline, end of phase 1, post washout and end of phase 2
Time frame: IL-8 measured in processed induced sputum.
Change in Thoracic Bioelectrical Impedance Spectroscopy Phase Angle
Exploratory TBIS measure obtained using the BodyStat Multiscan 500 to assess feasibility and physiological coherence relative to standard respiratory measures
Time frame: Baseline, end of phase 1, post washout and end of phase 2. And supplementary changes during hypertonic saline challenge testing
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Jul 2026, 2 months later.
Of 599 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 2 months is below that.
Counting every sponsor, half of 649 studies reached it within 23 months; a quarter within 10 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Astaxanthine
Middlesex University